[17]陈冬梅.成都地区成人1型糖尿病患者治疗方案的选择及血糖达标率[J]．临床医学研究与实践，2019，4（6）：195-196．DOI：10./.

[18]EL HAGE L，KASHYAP S R，RAO P.Use of SGLT-2 inhibitors in patients with type 1 diabetes mellitus[J]．J Prim Care Community Health，2019，10：2158．DOI：10.1177/2158.

[19]FERRANNINI E，SOLINI A.SGLT2 inhibition in diabetes mellitus：rationale and clinical prospects[J]．Nat Rev Endocrinol，2012，8（8）：495-502．DOI：10.1038/

[20]EPSTEIN B，ROSENWASSER R，SUTTON D，et al．SGLT-2 inhibitors and their potential in the treatment of diabetes[J]．Diabetes Metab Syndr Obes：Targets Ther，2013，6：453-467．DOI：10.2147/dmso.s.

[21]MUDALIAR S，ARMSTRONG D A，MAVIAN A A，et al．Remogliflozin etabonate，a selective inhibitor of the sodiumglucose transporter 2，improves serum glucose profiles in type 1 diabetes[J]．Diabetes Care，2012，35（11）：2198-2200．DOI：10.2337/dc12-0508.

[22]HENRY R R，THAKKAR P，TONG C，et al．Efficacy and safety of canagliflozin，a sodium-glucose cotransporter 2 inhibitor，as addon to insulin in patients with type 1 diabetes[J]．Diabetes Care，2015，38（12）：2258-2265．DOI：10.2337/dc15-1730.

[23]PERKINS B A，CHERNEY D Z，PARTRIDGE H，et al．Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes：results of an 8-week open-label proof-of-concept trial[J]．Diabetes Care，2014，37（5）：1480-1483．DOI：10.2337/dc13-2338.

[24]RODBARD H W，PETERS A L，SLEE A，et al．The effect of canagliflozin，a sodium glucose cotransporter 2 inhibitor，on glycemic end points assessed by continuous glucose monitoring and patientreported outcomes among people with type 1 diabetes[J]．Diabetes Care，2017，40（2）：171-180．DOI：10.2337/dc16-1353.

[25]ROSENSTOCK J，MARQUARD J，LAFFEL L M，et al．Empagliflozin as adjunctive to insulin therapy in type 1 diabetes：the EASE trials[J]．Diabetes Care，2018，41（12）：2560-2569．DOI：10.2337/dc18-1749.

[26]MATHIEU C，DANDONA P，GILLARD P，et al．Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes （the DEPICT-2 study）：24-week results from a randomized controlled trial[J]．Diabetes Care，2018，41（9）：1938-1946．DOI：10.2337/dc18-0623.

[27]DANDONA P，MATHIEU C，PHILLIP M，et al．Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes （DEPICT-1）：24 week results from a multicentre，doubleblind，phase 3，randomised controlled trial[J]．Lancet Diabetes Endocrinol，2017，5（11）：864-876．DOI：10.1016/S2213-8587（17）-X.

[28]HENRY R R，ROSENSTOCK J，EDELMAN S，et al．Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes：a randomized，double-blind，placebo-controlled pilot study[J]．Diabetes Care，2015，38（3）：412-419．DOI：10.2337/dc13-2955.

[29]ARAKI E，WATADA H，UCHIGATA Y，et al．Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes （DEPICT-5）：52-week results from a randomized，openlabel，phase Ⅲ clinical trial[J]．Diabetes Obes Metab，2020，22（4）：540-548．DOI：10.1111/dom..

[30]RODBARD glucose monitoring：a review of recent studies demonstrating improved glycemic outcomes[J]．Diabetes Technol Ther，2017，19（S3）：S25-37．DOI：10.1089/

[31]FAMULLA S，PIEBER T R，EILBRACHT J，et exposure and variability with empagliflozin as adjunct to insulin in patients with type 1 diabetes: continuous glucose monitoring data from a 4-week，randomized， placebo-controlled trial（EASE-1）[J]．Diabetes Technology & Therapeutics，2017，19（1）：：10.1089/

[32]MATHIEU C，DANDONA P，PHILLIP M，et al．Glucose variables in type 1 diabetes studies with dapagliflozin：pooled analysis of continuous glucose monitoring data from DEPICT-1 and -2[J]．Diabetes Care，2019，42（6）：1081-1087．DOI：10.2337/dc18-1983.

[33]ZINMAN B，WANNER C，LACHIN J M，et al．Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes[J]．N Engl J Med，2015，373（22）：2117-2128．DOI：10.1056/nejmoa.

[34]NEAL B，PERKOVIC V，MAHAFFEY K W，et al．Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]．N Engl J Med，2017，377（7）：644-657．DOI：10.1056/NEJMoa.

[35]PERKOVIC V，JARDINE M J，NEAL B，et al．Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]．N Engl J Med，2019，380（24）：2295-2306．DOI：10.1056/NEJMoa.

[36]WIVIOTT S D，RAZ I，BONACA M P，et al．Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]．N Engl J Med，2019，380（4）：347-357．DOI：10.1056/NEJMoa.

[37]VAN RAALTE D H，BJORNSTAD P，PERSSON F，et al．The impact of sotagliflozin on renal function，albuminuria，blood pressure，and hematocrit in adults with type 1 diabetes[J]．Diabetes Care，2019，42（10）：1921-1929．DOI：10.2337/dc19-0937.

文章来源：《糖尿病天地(临床)》 网址: http://www.tnbtd.cn/qikandaodu/2021/0119/564.html